Wockhardt Limited, a pharmaceutical and biotech company, manufactures and markets pharmaceuticals, medicinal, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules; and active pharmaceutical ingredients. The company's biopharmaceutical products include Glaritus, a long-acting biosimilar glargine; Wosulin, a recombinant human insulin; Wepox, an r-DNA erythropoietin; human insulin; and Biovac-B, a hepatitis B vaccine. Its pipeline also includes long-acting insulin analogues, concentrated insulins, GLP1 analogues, haemopoietins, biobetters and novel products, and delivery devices. It also provides contract manufacturing services. The company was founded in 1967 and is headquartered in Mumbai, India.

Mr. Neeraj  Agarwal

Chief Human Resource Officer

Mr. Anil V. Kamath AMRSH (Lon.), BCom (Hons), MBIM (Lon.), MIMA

Senior Vice President of Business Development

Dr. Mahesh V. Patel

Chief Scientific Officer of New Drug Discovery

Mr. Deepak R. Madnani

Chief Financial Officer

Ms. Debolina  Partap

Senior Vice President of Legal

Mr. Prakash  Gupta

President of Supply Chain

Mr. Zoher T. Sihorwala

Head of Global Regulatory Affairs

Dr. Habil Fakhruddin Khorakiwala

Founder & Executive Chairman

Dr. Murtaza Habil Khorakiwala

MD & Executive Director

Dr. Huzaifa Habil Khorakiwala

Executive Director

Wockhardt Limited

Wockhardt Limited 経営体制

経営情報